News center

1、 Policy tightening: National Health Commission strengthens safety supervision

In March 2025, the National Health Commission released the "Medical Quality and Safety Improvement Goals", which for the first time listed "reducing the incidence of injection cosmetic complications" as a core indicator in the field of plastic surgery and beauty, and introduced five compliance strategies. New regulations require:

Institutional qualification: The operating site must hold a "Medical Institution Practice License", and the diagnosis and treatment subjects clearly include "Medical Aesthetics Department".

Physician Certification: Operators must possess a Physician Qualification Certificate and be registered as the chief physician in charge of medical beauty treatments, and their qualifications must be verified through an online database.

Product traceability: Injection products must be labeled with the certification mark of the National Medical Products Administration (such as "Medical Device Approval") and achieve full process traceability through the UDI (Unique Device Identification) system.

Data shows that in 2024, the number of serious complications (such as vascular embolism and infection) caused by irregular injections in China will decrease by 18% compared to 2023, but illegal institutions' "three no operations" (unqualified, unregulated, and unprotected) still account for 67% of violations.

2、 Technological breakthrough: iteration from "filling" to "regeneration"

Experience of non-invasive technological innovation

The non porous water light needle technology replaces traditional needles with "microchannel array+precise pressure control", reducing the epidermal permeation pore size to 50 μ m and shortening the postoperative recovery period by 70%. Clinical data shows that the retention period of hyaluronic acid has been extended to 15 days, and the mesodermal permeability has increased to 82%. A 42 year old user of a medical beauty institution in Shenzhen gave feedback: "You can socialize without makeup on the second day after surgery, completely subverting the traditional nursing model

Regenerated materials lead the anti-aging revolution

PLLA: Stimulates collagen regeneration efficiency to increase by 40%, with a market size expected to exceed 3 billion yuan by 2025.

Girl's Needle (PCL): The latest domestically approved "injectable poly (ε - caprolactone) microsphere filler" by Sihuan Pharmaceutical, achieving a dual effect of "instant filling+long-term regeneration", with a maintenance time of over 1 year, has become a strong competitor to "Yiyan Shi" of East China Medicine.

Collagen regeneration technology: Shanxi Jinbo Biotechnology's recombinant type III humanized collagen freeze-dried fibers fill the gap in domestically developed biomaterials and are suitable for repairing dynamic wrinkles on the forehead.

Upgrading to Intelligence and Precision

The intelligent injection system uses AI skin detection to dynamically mix ingredients such as hyaluronic acid and PDRN, achieving precise delivery of "cocktail therapy"; Intraoperative ultrasound imaging navigation technology can control the embedding error within 0.3mm.

3、 Market pattern: domestic substitution accelerates, capital flows upstream

The process of localization is accelerating

By 2025, the market share of domestically produced beauty needles will increase to 58%, and companies such as Sihuan Pharmaceutical, Huadong Pharmaceutical, and Aimeike will break the import monopoly through technological breakthroughs. For example, after the approval of the "Girls' Needle" of Sihuan Medicine, the price of imported similar products will be reduced by 20%.

Capital focuses on technological innovation

Only Three Biosciences, a synthetic biotechnology company, has completed a billion yuan Pre-A round of financing to accelerate the research and development of ergothioneine raw materials; Capital is simultaneously pouring into the fields of recycled materials and smart devices. In 2024, there were over 28 upstream financing deals for medical beauty, involving a total amount of over 5 billion yuan.

Youthfulness of consumer groups

The post-90s and post-00s generations account for 52% of the injection beauty consumer group, driving the compound annual growth rate of the non-surgical light medical beauty market to 17%. According to e-commerce platform data, the online medical beauty consultation volume will increase by 36% year-on-year in 2025.

4、 Security Challenges and Future Trends

Smuggling and illegal injection hazards

In April 2025, Futian Port in Guangdong Province seized 20 sets of smuggled beauty injections wrapped around a man's waist. The products involved did not have Chinese labels or compliance approvals, highlighting the risk of a gray industry chain. The National Medical Products Administration reminds that illegal products may lead to serious complications such as granulomas and blindness.

Industry standardization and inclusiveness

With the full coverage of UDI system and the promotion of centralized procurement policy, the price of compliant products is expected to decrease by 30%, and the injection cost of recycled materials is expected to drop from 15000 yuan per injection to below 8000 yuan.

Technology integration and globalization

In the next five years, biodegradable materials (such as PDLLA) and gene editing anti-aging technology will be deeply integrated with AI diagnosis, driving the Chinese beauty needle industry from "following" to "leading".